Literature DB >> 21826070

Interventional cardiology: Antithrombotic drug and stent choices in primary PCI.

Daniel S Menees, Eric R Bates.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21826070     DOI： 10.1038/nrcardio.2011.108

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  10 in total

1.  Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS-SWITCH analysis.

Authors:  George D Dangas; Roxana Mehran; Eugenia Nikolsky; Bimmer E Claessen; Alexandra J Lansky; Bruce R Brodie; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Dariusz Dudek; Martin Möckel; Adriano Caixeta; Helen Parise; Harvey White; Gregg W Stone
Journal:  J Am Coll Cardiol       Date:  2011-06-07       Impact factor: 24.094

2.  A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes.

Authors:  Marc Cohen; Kenneth W Mahaffey; Karen Pieper; Charles V Pollack; Elliott M Antman; James Hoekstra; Shaun G Goodman; Anatoly Langer; Jacques J Col; Harvey D White; Robert M Califf; James J Ferguson
Journal:  J Am Coll Cardiol       Date:  2006-09-12       Impact factor: 24.094

Review 3.  Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention.

Authors:  David P Faxon
Journal:  Catheter Cardiovasc Interv       Date:  2011-05-26       Impact factor: 2.692

4.  Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction.

Authors:  George D Dangas; Adriano Caixeta; Roxana Mehran; Helen Parise; Alexandra J Lansky; Ecaterina Cristea; Bruce R Brodie; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Dariusz Dudek; Martin Möeckel; Gregg W Stone
Journal:  Circulation       Date:  2011-04-11       Impact factor: 29.690

5.  Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial.

Authors:  Gregg W Stone; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; George Dangas; S Chiu Wong; Martin Fahy; Helen Parise; Roxana Mehran
Journal:  Lancet       Date:  2011-06-12       Impact factor: 79.321

6.  Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.

Authors:  Harvey D White; Derek P Chew; James W Hoekstra; Chadwick D Miller; Charles V Pollack; Frederick Feit; A Michael Lincoff; Michel Bertrand; Stuart Pocock; James Ware; E Magnus Ohman; Roxana Mehran; Gregg W Stone
Journal:  J Am Coll Cardiol       Date:  2008-05-06       Impact factor: 24.094

7.  Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.

Authors:  Roxana Mehran; Alexandra J Lansky; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; S Chiu Wong; Eugenia Nikolsky; Louise Gambone; Lynn Vandertie; Helen Parise; George D Dangas; Gregg W Stone
Journal:  Lancet       Date:  2009-08-28       Impact factor: 79.321

8.  Bivalirudin during primary PCI in acute myocardial infarction.

Authors:  Gregg W Stone; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; George Dangas; S Chiu Wong; Ajay J Kirtane; Helen Parise; Roxana Mehran
Journal:  N Engl J Med       Date:  2008-05-22       Impact factor: 91.245

9.  Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial.

Authors:  George Dangas; Roxana Mehran; Giulio Guagliumi; Adriano Caixeta; Bernhard Witzenbichler; Jiro Aoki; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; LeRoy E Rabbani; Helen Parise; Gregg W Stone
Journal:  J Am Coll Cardiol       Date:  2009-10-06       Impact factor: 24.094

10.  Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.

Authors:  A Michael Lincoff; Steven R Steinhubl; Steven V Manoukian; Derek Chew; Charles V Pollack; Frederick Feit; James H Ware; Michel E Bertrand; E Magnus Ohman; Walter Desmet; David A Cox; Roxana Mehran; Gregg W Stone
Journal:  JACC Cardiovasc Interv       Date:  2008-12       Impact factor: 11.195
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.